贝伐珠单抗、呋喹替尼致高血压、肾病综合征1例  

Hypertension and nephrotic syndrome induced by bevacizumab and fuquitinib:one case report

作　　者：梁紫微 吴娜 孟凡堰[1] LIANG Ziwei;WU Na;MENG Fanyan(Department of Pharmacy,Municipal People's Hospital,Guizhou Anshun 561000,China;Department of Oncology,Municipal People's Hospital,Guizhou Anshun 561000,China)

机构地区：[1]安顺市人民医院药剂科,贵州安顺561000 [2]安顺市人民医院肿瘤科,贵州安顺561000

出　　处：《中国医院药学杂志》2024年第15期1836-1839,共4页Chinese Journal of Hospital Pharmacy

摘　　要：通过1份老年男性患者使用贝伐珠单抗、呋喹替尼引起高血压、肾病综合征的病例资料与相关文献进行回顾分析。患者使用贝伐珠单抗、呋喹替尼后出现血压升高达190/110 mmHg、大量蛋白尿(17.36 g·d^(-1)),血清白蛋白降至24.4 g·L^(-1),双下肢水肿,考虑为贝伐珠单抗、呋喹替尼所致高血压、继发性肾病综合征可能性大,经停用呋喹替尼、血液净化治疗与对症支持处理后有所好转。提示贝伐珠单抗、呋喹替尼可能会导致高血压、肾病综合征,临床使用该类药物时需警惕类似药物不良反应的发生。Hypertension and nephrotic syndrome induced by bevacizumab and fuquitinib in an elderly male was analyzed with a review of the relevant literature. After dosing of bevacizumab and fuquitinib, there was an onset of elevated blood pressure(190/110 mmHg), massive proteinuria(17. 36 g·d^(-1)), lower level of serum albumin(24. 4 g·L^(-1)) and edema of both lower extremities. There was a high possibility of hypertension and secondary nephrotic syndrome due to bevacizumab and fuquitinib. The symptoms improved after a withdrawal of fuquinitinib, blood purification and symptomatic supports.

关 键 词：贝伐珠单抗 呋喹替尼 高血压 肾病综合征 抗VEGF抑制剂 

分 类 号：R969.3[医药卫生—药理学]